What Sets Advanced
Compounds Apart

Advanced compounds are those operating at mechanistic frontiers — either newer mechanisms without established precedent, or highly targeted interventions addressing specific molecular events in aging, metabolism, or cellular biology. They're not necessarily more effective than established compounds. They're more specific, more novel, or addressing research questions that older compounds weren't designed to answer.

FOXO4-DRI is the most mechanistically precise anti-aging compound in the catalog. It doesn't slow aging generally — it kills the specific cells driving it. Senescent cells (those that stopped dividing but resist apoptosis) accumulate with age and secrete SASP — a chronic inflammatory cocktail that damages surrounding tissue. FOXO4-DRI disrupts the FOXO4-p53 interaction that keeps senescent cells alive, selectively triggering their apoptosis while leaving healthy cells unaffected. The 2017 Nature paper from van Deursen's lab remains the landmark demonstration of this mechanism.

It represents a different philosophy from longevity compounds like NAD+ or Epitalon — rather than restoring declining function, it removes the cellular debris actively accelerating decline.

SLU-PP-332 targets ERRα — the transcription factor that governs the entire gene network activated by aerobic exercise. Compounds like MOTS-c and metformin activate AMPK, which is downstream of where exercise actually starts at the gene regulation level. SLU-PP-332 goes further upstream, activating the master switch. Preclinical data shows measurable endurance improvement in sedentary mice — not through structural adaptation but through metabolic reprogramming.

MOTS-c is remarkable for a different reason: it's encoded in mitochondrial DNA. It's the first mitochondria-derived peptide shown to function as a systemic hormone — communicating mitochondrial status to the rest of the body. Its AMPK activation and decline with age make it both an exercise research tool and a longevity research target.

SS-31 (Elamipretide) is the most mechanistically precise mitochondrial compound available. It physically concentrates in the inner mitochondrial membrane — a compartment most drugs and peptides cannot reach — and stabilizes cardiolipin, the phospholipid that organizes the electron transport chain. Phase 2 human data in heart failure and mitochondrial myopathy validates the target.

BAM15 approaches mitochondrial biology from a completely different angle — uncoupling the proton gradient rather than protecting the ETC. By allowing protons to leak past ATP synthase, it forces cells to burn more fuel to maintain energy output. The key advance over historical uncouplers (DNP) is selectivity — BAM15 concentrates in mitochondria at doses well below plasma toxicity threshold.

Retatrutide adds glucagon receptor agonism to the GIP+GLP-1 dual mechanism of tirzepatide — a triple agonist producing 24.2% body weight reduction in Phase 2 TRIUMPH trials. The glucagon component adds thermogenesis (energy expenditure) to the appetite suppression and insulin sensitization of the other two receptors. It's the current frontier of incretin-based metabolic research.

Cagrilintide takes a different approach — rather than adding more incretin receptors, it adds amylin, an entirely separate satiety hormone acting on the area postrema rather than the hypothalamus. The CagriSema combination (cagrilintide + semaglutide) achieves 22.7% weight reduction by hitting two non-overlapping satiety pathways simultaneously.

5-Amino-1MQ is the most conceptually novel metabolic compound in the catalog. NNMT (nicotinamide N-methyltransferase) is overexpressed in obese fat cells — it consumes NAD+ precursors and adds epigenetic methyl marks that lock adipocytes in an energy-storing state. Inhibiting NNMT reprograms fat cells at the chromatin level, shifting gene expression toward fat oxidation. Preclinical data shows fat mass reduction without reduced food intake — a purely metabolic mechanism with no appetite component.